Unicycive shares edge up as biotech looks to June FDA meeting and analyst lifts target
Unicycive Therapeutics shares didn’t move much in premarket trading Thursday. Benchmark lifted its price target, but attention stayed on an upcoming U.S. regulatory decision expected this month. The Nasdaq-listed kidney-drug maker traded at $7.20 by 6:34 a.m. EDT, off 0.4% from its last close. At the same time, the SPDR S&P Biotech ETF, a common biotech benchmark, was up 1.6% in early moves.